ELAMADRID is a research program directed towards the discovery and development of effective therapeutic agents for treating amyotrophic lateral sclerosis (ALS), a rare mortal neurodegenerative disease which currently incurable. Our multidisciplinary research team, which includes experts in Drug Design and Synthesis, Cell Biology, Pharmacology and Neurology from different research institutes, universities and hospitals, has all the expertise and instrumentation necessary to achieve the proposed objectives and pass the results on patients and society.

ALS is a disease that is caused by the damage and subsequent selective and progressive loss of motorneurons, both upper and lower. The development of the disease is very fast, being the life expectancy after the diagnosis around three years.

Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and ALS represent one of the most important social challenges to balance life expectancy with health expectancy. Therefore, the development of advanced biomarkers, new drugs and technologies is key to establish a treatment for these diseases, which are currently an important social challenge.

The most recent discoveries regarding the molecular pathology of ALS have revealed a severe disequilibrium in the homeostatsis of several proteins of the nervous system, caused by inflammatory processes or oxidative stress, which lead to the progressive death of motorneurons.

Up until now, several scientific factors; namely, the lack of adequate model systems and interdisciplinary collaboration, as well as the poor economic return from investigating a rare disease like ALS, account for why no effective treatments have been developed. Our proposed project aims to provide a new technology for this field of health by developing well characterized human cell models that will afford the discovery and characterization of effective drugs for treating ALS.

We anticipate that this project’s results will have a major impact on the investigation of new drugs for ALS and related pathologies, such as frontotemporal dementia, Alzheimer or Parkinson diseases.







Ana Martínez (This email address is being protected from spambots. You need JavaScript enabled to view it.)

Gestora del Proyecto:

Nuria Mª Rivas (This email address is being protected from spambots. You need JavaScript enabled to view it.)

Centro de Investigaciones Biológicas (CIB-CSIC)

C/Ramiro de Maeztu, 9

28006 MADRID







             Proyecto ELA-MADRID.B2017/BMD-3813


 Proyecto financiado por la Comunidad de Madrid y la Unión Europea